v3.25.1
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Cumulative adjustment from adoption of ASC 326
Arbuz Group LLP ("Arbuz")
ReKassa
Total equity attributable to the shareholders'
Total equity attributable to the shareholders'
Cumulative adjustment from adoption of ASC 326
Total equity attributable to the shareholders'
Arbuz Group LLP ("Arbuz")
Common Stock
Additional paid in capital
Retained earnings
Retained earnings
Cumulative adjustment from adoption of ASC 326
Retained earnings
Arbuz Group LLP ("Arbuz")
Accumulated other comprehensive loss
Non-controlling interest
Non-controlling interest
Arbuz Group LLP ("Arbuz")
Non-controlling interest
ReKassa
Shares issued, beginning of period (in shares) at Mar. 31, 2022               59,542,212                
Equity, beginning of period at Mar. 31, 2022 $ 546,608       $ 553,603     $ 59 $ 174,745 $ 441,924     $ (63,125) $ (6,995)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Stock based compensation (in shares)               57,216                
Stock based compensation 11,038       11,038       11,038              
Contribution of shareholder 677       677       677              
Issuance of shares of common stock (in shares)               59,763                
Issuance of shares of common stock 4,290       4,290       4,290              
Acquisition of insurance companies (26,588)       (26,588)       (26,588)              
Other comprehensive income (1,485)       (1,485)               (1,485)      
Reclassification of loss from cumulative translation adjustment of discontinued operations 25,415       25,415               25,415      
Foreign currency translation adjustments, net of tax effect 5,195       5,195               5,195      
Net income 205,586       205,140         205,140       446    
Shares issued, end of period (in shares) at Mar. 31, 2023               59,659,191                
Equity, end of period at Mar. 31, 2023 770,736 $ (22,772)     777,285 $ (22,772)   $ 59 164,162 647,064 $ (22,772)   (34,000) (6,549)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Stock based compensation (in shares)               662,622                
Stock based compensation 19,627       19,627     $ 1 19,626              
Disposal of FF Ukraine 0       (6,549)         (6,549)       6,549    
Purchase of subsidiary shares     $ 9,097 $ 256     $ 5,457         $ 5,457     $ 3,640 $ 256
Other comprehensive income 2,987       2,987               2,987      
Foreign currency translation adjustments, net of tax effect 12,075       12,075               12,075      
Net income $ 374,952       375,540         375,540       (588)    
Shares issued, end of period (in shares) at Mar. 31, 2024 60,321,813             60,321,813                
Equity, end of period at Mar. 31, 2024 $ 1,166,958       1,163,650     $ 60 183,788 998,740     (18,938) 3,308    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Delivered stock awards from previous year (in shares)               215,878                
Delivered stock awards from previous year 3,092       3,092       3,092              
Forfeited stock based compensation (in shares)               (310,700)                
Forfeited stock based compensation 0                              
Stock based compensation (in shares)               765,958                
Stock based compensation 59,593       59,593     $ 1 59,592              
Other compensation (in shares)               1,000                
Other compensation 138       138       138              
Purchase of subsidiary shares     $ (887)       $ 2,175         $ 2,175     $ (3,062)  
Other comprehensive income 5,045       5,045               5,045      
Foreign currency translation adjustments, net of tax effect (104,102)       (104,102)               (104,102)      
Net income $ 84,521       84,650         84,650       (129)    
Shares issued, end of period (in shares) at Mar. 31, 2025 60,993,949             60,993,949                
Equity, end of period at Mar. 31, 2025 $ 1,214,358       $ 1,214,241     $ 61 $ 246,610 $ 1,085,565     $ (117,995) $ 117